JHVEPhoto When I last wrote about the pharmaceuticals company Bristol-Myers Squibb (NYSE:BMY) in June, there appeared little impetus for a price uptick. The company had made a shock earnings outlook downgrade for 2024 following massive acquisition related charges, resulting in an impossibly high forward non-GAAP price-to-earnings (P/E) ratio for the year. This meant that before a re-normalisation of its EPS in 2025, there was little else foreseeable that could surprise about BMY. I was wrong. The stock ...

John Scott/DigitalVision via Getty ImagesDespite lingering skepticism about Bristol-Myers Squibb's future (NYSE:BMY) on Wall Street in recent months, fueled by investor concerns about Eliquis facing patent expirations in 2026, the company pleasantly surprised me with its second-quarter financial results, thanks in part to strong sales in its cardiovascular franchise that offset a muted 11% year-over-year sales growth in its blockbuster PD-1 inhibitor Opdivo due to increasing competition from Merck's Key ...

From a technical perspective, Bristol Myers Squibb (BMY) is looking like an interesting pick, as it just reached a key level of support. BMY recently overtook the 200-day moving average, and this suggests a long-term bullish trend.A useful tool for traders and analysts, the 200-day simple moving average helps determine long-term market trends for stocks, commodities, indexes, and other financial instruments. It moves higher or lower in conjunction with longer-term price performance, and serves as a support ...

gawrav Buying headline-making growth stocks can be fun while they are on their way up. But with so many eyeballs on those names, one has to wonder whether if all the positivity is already baked into the share price, as may be the case with NVIDIA (NVDA) at today’s prices. While it’s great to see a ton of growth in year 1, what if years 2-10 are followed by mediocre returns? Moreover, too high a share price combined with a low dividend yield makes for inadequate return potential through dividend reinvest ...

Core Viewpoint - The aging U.S. population is a significant driver for the healthcare sector, leading to increased demand for specific healthcare companies that cater to the elderly [1] Group 1: Bristol Myers-Squibb (BMY) - In 2021, the U.S. Medicare program spent $216 billion on subsidized prescriptions for seniors, with BMY receiving $12.6 billion for its blood-thinning drug Eliquis, accounting for over 25% of its $46 billion revenue [2] - The demand for blood thinners is expected to rise as more individuals enter the age bracket where such medications are necessary [2] - Medicare also paid $5.9 billion for BMY's Revlimid, a treatment for multiple myeloma, which is prevalent among seniors [2][3] Group 2: Eli Lilly (LLY) - Eli Lilly's Mounjaro, a weight loss drug, and its Trulicity diabetes drug, which generated $4.7 billion in Part D-covered prescriptions, position the company for long-term success [4] - Eli Lilly has negotiated new pricing with the federal government for its drugs, effective in 2026, which may enhance its sales potential [5] Group 3: Tenet Healthcare (THC) - Tenet Healthcare operates a large and diversified healthcare service network, including over 535 ambulatory surgery centers and 52 hospitals [6] - THC has experienced over 100% share value growth year-to-date and is projected to reach a valuation of $200 per share with continued performance [6][7] - The company is expected to grow as it acquires more facilities to meet the demands of the aging U.S. population [7]

Core Insights - The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) to determine which stock is a better undervalued investment option [1] - BMY has a stronger Zacks Rank of 2 (Buy) compared to VRTX's Zacks Rank of 3 (Hold), indicating a more favorable earnings estimate revision trend for BMY [1] Valuation Metrics - BMY has a forward P/E ratio of 89.98, while VRTX has a significantly higher forward P/E of 259.45 [2] - The PEG ratio for BMY is 18, compared to VRTX's PEG ratio of 20.29, suggesting BMY may offer better value relative to its expected earnings growth [2] - BMY's P/B ratio is 6, while VRTX's P/B ratio is 6.94, indicating BMY's market value is more favorable compared to its book value [2] Value Grades - BMY holds a Value grade of B, whereas VRTX has a Value grade of D, further supporting the argument that BMY is the superior value option at this time [3] - The improving earnings outlook for BMY enhances its attractiveness in the context of the Zacks Rank model [3]

A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program.If you're looking for a way to permanently boost your passive income stream, you've probably seen Bristol Myers Squibb (BMY -2.91%) when you screen for stocks that pay big dividends.At recent prices, the Big Pharma stock offers a 4.7% yield. Unfortunately, dividend payers rarely offer such high yields unless there are reasons to suspect they can't maintain their payout-raisi ...

JHVEPhoto/iStock Editorial via Getty Images Bristol-Myers Squibb Company (NYSE:BMY) crossed $50 / share after a double-digit share price increase on the back of strong earnings. We recently discussed the company, highlighting how shareholders are too focused on the long term instead of celebrating its strength today. The company's recent Q2 earnings highlight how it can drive immediate and strong shareholder returns. Bristol-Myers Squibb 2Q 2024 Performance The company has achieved strong 2Q 2024 perfor ...

Bristol-Myers Squibb Co BMY on Friday reported upbeat second-quarter results.The report came amid an exciting earnings season. Here are some key analyst takeaways.Barclays On Bristol-Myers SquibbAnalyst Carter Gould downgraded the rating to Underweight, while maintaining the price target at $41.Gould explained the downgrade, stating that the recent rally in Bristol-Myers Squibb’s stock, “despite little movement in underlying post-2025 fundamentals,” appears to be “an over-reaction to the IRA news.”The compa ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Barclays analyst Carter Gould downgraded the rating for Bristol-Myers Squibb Company BMY from Equal-Weight to Underweight and maintained the price target of $41. Bristol-Myers Squibb shares gained 11.4% to settle at $50.45 on Friday. See how other analysts view this stock. See how other analysts view this sto ...